The Latest in CLL

Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL

June 23, 2020

CLL

Three-drug combo promising against high-risk CLL

June 15, 2020

CLL

MCC response varies based on immunosuppression type, especially CLL

June 2, 2020

CLL

Race and location appear to play a role in the incidence of CLL and DLBCL

May 20, 2020

Interleukin-27 increased cytotoxic effects of bone marrow NK cells in CLL

May 6, 2020

CLL

FDA approves ibrutinib-rituximab combo for newly diagnosed CLL, SLL in adults

April 22, 2020

CLL

Five prognostic indexes come up short for planning early CLL treatment

April 22, 2020

CLL

One-third of high-risk CLL patients received treatment counter to recommendations

April 8, 2020

CLL

Case study shows CLL may mask COVID-19 infection

April 3, 2020

CLL

CLL and breast cancer differ in the expression of regulatory microRNAs

March 25, 2020

CLL

NMA haploidentical allo-BMT plus post-transplant cyclophosphamide deemed safe, effective for CLL

March 11, 2020

CLL

Safer CAR uses modified NK cells for advanced CLL, NHL

February 19, 2020

Novel mutations contribute to progression of venetoclax-treated CLL

February 2, 2020

CLL

Ofatumumab works safely for elderly patients with CLL, comorbidities

January 22, 2020

CLL

CAR T-cell therapy may worsen mental health in some patients

January 21, 2020

CLL